| dc.description.abstract | Herbal-derived medicines have introduced as sources of novel drugs due to minimum systemic side effects. Silibinin
as a flavonoid compound has showed with effective chemotherapeutic effects on different cancers. Here, we investigated
the impact of combination therapy of silibinin, with paclitaxel and cisplatin in inhibition of proliferation and induction
of apoptosis in MCF-7 cells. Cell proliferation was assessed by MTT assay and the percentage of apoptotic cells was
measured using flowcytometric assay. Understand of molecular mechanism of this combination related to apoptotic
pathway were evaluated by Real Time RT-PCR assays. The IC50 values for silibinin, paclitaxel and cisplatin were
160 آ± 22.2 ?M, 33.7 آ± 4.2 nM and 3.2 آ± 0.5 ?M, respectively. Paclitaxel and cisplatin induced higher percentage of
apoptosis in MCF-7 (P < 0.05). Treatment of cell line with combination of silibinin and paclitaxel or cisplatin showed
enhanced early apoptosis 56% and 61%, respectively (P < 0.05). Gene expression patterns demonstrated a significant
decrease in anti-apoptotic Bcl-2 with increase in pro-apoptotic Bax, P53, BRCA1 and ATM mRNA levels. Taken
together combination therapy of breast cancer cells by applying paclitaxel or cisplatin with silibinin synergistically
increases the anti-proliferative effect of single agents. | |
